OMCL — Omnicell, Inc. Stock Price, Chart & AI Report

Positive Jan 5, 2026 • 20:33 UTC The Motley Fool • Sara Appino

Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs

Omnicell's EVP & Chief Legal/Admin Officer Corey Manley sold 6,106 shares worth $243,629 on December 3, 2025, reducing his direct holdings by 5.85%. The sale occurred as the stock approached 52-week highs following strong Q3 results and the announcement of the company's new Titan XT automated dispensing system, which prompted analyst upgrades.

OMCL insider trading medication management automation pharmacy robotics healthcare automation Form 4 filing stock sale analyst upgrade

Sentiment note

Despite the insider sale, the overall sentiment is positive due to strong Q3 earnings that exceeded expectations, recent product launch (Titan XT system), multiple analyst upgrades, stock trading near 52-week highs, and significant recovery from May lows. The insider sale appears routine and modest relative to holdings, not indicating loss of confidence in the company.

Neutral Aug 26, 2025 • 11:00 UTC GlobeNewswire Inc. • Daniel Kontoh-Boateng

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Evoke Pharma partnered with EVERSANA and Omnicell to expand access to GIMOTI nasal spray for gastroparesis treatment, targeting large gastroenterology practices and specialty pharmacies through strategic pharmacy network agreements.

EVOK OMCL gastroparesis nasal spray pharmaceutical partnership specialty pharmacy gastrointestinal treatment

Sentiment note

Providing pharmacy management services as part of a business partnership

Positive Jul 21, 2025 • 14:00 UTC GlobeNewswire Inc. • Towards Healthcare

Pharmacy Automation Market Surges with 10.12% CAGR; AI & Retail Pharmacy Demand Transform Dispensing in 2025

The global pharmacy automation market is projected to grow from USD 6.99 billion in 2025 to USD 16.65 billion by 2034, driven by technological advancements, chronic disease management, and the need to reduce medication errors.

AMZN MCK OMCL pharmacy automation AI integration medication dispensing healthcare technology market growth

Sentiment note

Provides advanced automated dispensing and medication management technologies

Positive Nov 3, 2024 • 14:28 UTC Benzinga • Lekha Gupta

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.

GSAT VFC MDGL PRCT mid-cap stocks Globalstar V.F. Corp Madrigal Pharmaceuticals

Sentiment note

Omnicell stock increased 23.22% after the company reported third-quarter results and raised its FY24 guidance above estimates.

Positive Sep 19, 2024 • 15:00 UTC GlobeNewswire Inc. • Globe Newswire

Adherence Packaging Market Size Expected to Reach USD 2.05 Billion by 2033

The global adherence packaging market size is expected to grow from $1.10 billion in 2023 to $1.93 billion by 2032, driven by the increasing number of chronic diseases and the need for quality medication. However, high costs and strict regulations pose challenges to the market's growth.

OMCL CAH MCK BAX adherence packaging chronic diseases medication regulations

Sentiment note

Omnicell, Inc. is listed as one of the top companies in the adherence packaging market, suggesting its strong position and potential for growth.

Unknown Jun 10, 2024 • 12:33 UTC Zacks Investment Research • Zacks Equity Research

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

OMCL RMD MEDP HIMS

Unknown Jun 6, 2024 • 15:31 UTC Zacks Investment Research • Zacks Equity Research

Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INSP OMCL

Unknown Jun 3, 2024 • 15:37 UTC Zacks Investment Research • Zacks Equity Research

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

OMCL RMD MEDP HIMS

Unknown May 6, 2024 • 12:02 UTC Zacks Investment Research • Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

OMI OMCL MEDP EHC

Unknown May 2, 2024 • 12:45 UTC Zacks Investment Research • Zacks Equity Research

Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

OMCL CCLD

Unknown Apr 30, 2024 • 11:30 UTC Zacks Investment Research • Zacks Equity Research

GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates

GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

GEHC OMCL

Unknown Mar 1, 2024 • 13:43 UTC Zacks Investment Research • Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

SYK DVA CAH OMCL